Apr 11, 2024
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Mar 19, 2024
PTC Therapeutics Provides Key Regulatory Updates
Feb 29, 2024
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Feb 22, 2024
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 15, 2024
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Jan 25, 2024
CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna(TM) (ataluren) Following Re-examination Procedure
Jan 08, 2024
PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference
Feb 16, 2021
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
Feb 04, 2021
PTC Therapeutics to Host Call to Review Results from its Study of Translarna(TM) (ataluren) in Patients with Nonsense Mutation Duchenne Muscular Dystrophy
Jan 11, 2021
PTC Therapeutics Provides Update on R&D Pipeline and Commercial Progress at 39th Annual J.P. Morgan Healthcare Conference
Jan 04, 2021
PTC Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Dec 18, 2020
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 04, 2020
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 30, 2020
PTC Therapeutics Announces Initiation of Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia
Nov 19, 2020
PTC Therapeutics to Present at the Evercore ISI 3rd Annual HealthCONx Conference
Nov 17, 2020
PTC Therapeutics Announces that PTC518 Has Entered into a Phase 1 Clinical Trial for the Huntington's Disease Program
Oct 29, 2020
PTC Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update
Oct 28, 2020
PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences
Oct 22, 2020
PTC Therapeutics and AADC Family Network Announce First-Ever AADC Deficiency Awareness Day in Massachusetts
Oct 21, 2020
Evrysdi(TM) (risdiplam) Continues to Make Global Progress for the Treatment of Spinal Muscular Atrophy